-
Hematol. Oncol. Clin. North Am. · Apr 2007
ReviewTrastuzumab (herceptin) for early-stage breast cancer.
- Gustavo Ismael, Daniela Dornelles Rosa, Evandro de Azambuja, Sofia Braga, and Martine Piccart-Gebhart.
- Medical Oncology Clinic, Jules Bordet Institute, l'Université Libre de Bruxelles, Boulevard de Waterloo, 125, 1000 Brussels, Belgium.
- Hematol. Oncol. Clin. North Am. 2007 Apr 1; 21 (2): 239-56.
AbstractBreast cancer patients who have HER2 gene amplification and, consequently, protein overexpression, generally show an aggressive course with short disease-free and overall survivals. Trastuzumab, a humanized monoclonal antibody against the extracellular domain of HER2 protein, has been shown to benefit patients who have HER2-positive metastatic breast cancer, and recently, the results of five adjuvant trials involving more than 13,000 women have been released. Here, the authors summarize the main results and outline the differences among these trials, which have demonstrated an important role of trastuzumab in the treatment of women who have HER2-overexpressing/amplified early breast cancer.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.